ERNA (Ernexa Therapeutics) Tariff Resilience Score: 8/10 (As of Jul. 07, 2026)


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.20
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Tariff Resilience Score?

Ernexa Therapeutics ERNA -3.73% 30 Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,368 Biotechnology companies, Ernexa Therapeutics ranks better than 98.68% on this metric.

Ernexa Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Ernexa Therapeutics has Ernexa Therapeutics Inc has limited exposure to tariffs as its operations are primarily domestic. The pharmaceutical industry often benefits from tariff exemptions, and the company has strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ernexa Therapeutics might have Highly Resilient.

Ernexa Therapeutics  (NAS:ERNA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ernexa Therapeutics Tariff Resilience Score Related Terms

ERNA vs PMCB, SYBX, ASBP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Ernexa Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ernexa Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Ernexa Therapeutics's Tariff Resilience Score falls into.


ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Ernexa Therapeutics (ERNA) has a Tariff Resilience Score of 8 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Ernexa Therapeutics ranks #18 out of 1368 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Ernexa Therapeutics' Tariff Resilience Score too high?
Ernexa Therapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Ernexa Therapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #18 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Tariff Resilience Score compare to PMCB and SYBX?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #18 out of 1368 companies for Tariff Resilience Score. This places Ernexa Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Ernexa Therapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.20
Price